{"url_path":"/sec/juns/8-k/2026-06-30/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-031312-index.html","accession_number":"0001493152-26-031312","cik":"0001679628","ticker":"JUNS","issuer_name":"JUPITER NEUROSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-031312-index.html","primary_entity_key":"0001679628","primary_entity_name":"JUPITER NEUROSCIENCES, INC."},"word_count":661,"has_tables":true,"body_markdown":"**Item\n5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of\nCertain Officers.**\n\n \n\n*Appointment\nof Director*\n\n* *\n\nOn\nJune 26, 2026, the Board of Directors (the “Board”) of Jupiter Neurosciences, Inc. (the “Company”) appointed\nTomas J. Philipson, Ph.D. to serve as a member of the Board, effective immediately. Dr. Philipson will serve until the next annual meeting\nof stockholders and until his successor is duly elected and qualified, or his earlier death, resignation, or removal.\n\n \n\nIn\nconnection with his appointment, Dr. Philipson was also appointed to serve as a member of the Audit Committee and the Compensation Committee\nof the Board, in each case effective on the same date as his appointment to the Board.\n\n \n\nDr.\nPhilipson, age 64, is a health care economist with experience across academia, government, and the private sector. Since June 2020, Dr.\nPhilipson has been self-employed through his consulting firm, TJP Economic Consulting Inc., where he advises senior executives at biopharmaceutical\nand health care companies on economic and policy matters. Dr. Philipson currently serves as Managing Partner of MEDA Ventures since 2023.\nDr. Philipson serves on the advisory boards of Diagnos Inc. since 2025, GATC Health Corp. (Medical Advisory Board) since 2022, iRemedy\nHealthcare Companies, Inc. since 2021, Epigenetix, Inc. since 2021, Nested Knowledge, Inc. since 2022, and M2i Global, Inc. since 2024.\nHe is also a member of the Anthropic Economic Advisory Council since 2025. Dr. Philipson co-founded Precision Health Economics LLC in\n2007 and served as Managing Partner until its acquisition in 2015. Dr. Philipson previously served in senior roles in the U.S. federal\ngovernment, including as Acting Chairman of the White House Council of Economic Advisers from June 2019 to June 2020 and as a member\nof the Council of Economic Advisers from 2017 to 2020. Earlier in his career, he served as a senior economic advisor to the leadership\nof the U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services in 2003 and 2004. He was appointed to the\nKey Indicator Commission of the U.S. Congress in 2012 and has served as a scientific advisor to the House of Representatives’ 21st\nCentury Cures initiative (2015) and the Biden Cancer Initiative (2017). Dr. Philipson is the Daniel Levin Chair of Public Policy Emeritus\nat the University of Chicago, where he held appointments in the Department of Economics, the Law School, and the Harris School of Public\nPolicy. Dr. Philipson received a B.A. in Mathematics from Uppsala University, an M.A. in Mathematics from Claremont Graduate University,\nand an M.A. and Ph.D. in Economics from the Wharton School of the University of Pennsylvania.\n\n \n\nIn\nconnection with his appointment to the Board, Dr. Philipson will receive the following equity compensation in lieu of participating in\nthe Company’s standard cash compensation program for non-employee directors: (i) a sign-on option to purchase 90,000 shares of\nthe Company’s common stock at an exercise price equal to the fair market value on June 29, 2026 (the “Grant Date”),\nvesting in equal quarterly installments over 36 months, subject to continued service as a director; and (ii) in lieu of cash compensation\notherwise payable as an annual cash retainer and committee fees, an option to purchase 446,428 shares of the Company’s common stock\nat an exercise price equal to the fair market value on the Grant Date, vesting in equal quarterly installments over 36 months,\nsubject to continued service as a director.\n\n \n\nOther\nthan the foregoing compensation arrangements, there are no arrangements or understandings between Dr. Philipson and any other persons\npursuant to which he was selected as a director, and there are no transactions involving Dr. Philipson requiring disclosure under Item\n404(a) of Regulation S-K.\n\n \n\n*Committee\nComposition*\n\n \n\nEffective\nJune 26, 2026, the Board’s committees are composed as follows:\n\n \n\nAudit\nCommittee\n \nCompensation\nCommittee\n \nNominating\nand Governance Committee\n\nHolger\nWeis (Chair)\n \nNicholas\nHemmerly (Chair)\n \nJulie\nKampf (Chair)\n\nNicholas\nHemmerly\n \nJulie\nKampf\n \nHolger\nWeis\n\nTomas\nJ. Philipson, Ph.D.\n \nTomas\nJ. Philipson, Ph.D.\n \nNicholas\nHemmerly"}